There were 628 press releases posted in the last 24 hours and 150,697 in the last 365 days.

CORRECTION: Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors

/EIN News/ -- CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Unum Therapeutics Inc. (NASDAQ: UMRX), please note the investors event date has been changed from November 12 to November 19 in the first paragraph. The corrected release follows.

Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced that the Company will host an investor event to discuss its efforts in solid tumors on Monday November 19, 2018, from 8:30 a.m. to 10:00 a.m. ET in New York City.

The event will feature guest speaker Charles S. Fuchs, MD, MPH, Director of the Yale Cancer Center, who will discuss the challenges and opportunities in HER2 malignancies. In addition, the Company will discuss the unmet need, clinical validation of ACTR707 and design of the ATTCK-34-01 Phase I trial using ACTR707 in combination with trastuzumab to target HER2-positive advanced cancers. The Company also will provide more details on the new BOXR platform to support its growing efforts in solid tumors.

To join the live webcast, please visit the investor relations section of the Unum Therapeutics website at https://investors.unumrx.com/ at least 10 minutes before the event begins.

About Unum Therapeutics

Unum Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Unum’s novel proprietary technologies include Antibody-Coupled T cell Receptor (ACTR), a universal, engineered cell therapy intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types, and Bolt-On Chimeric Receptor (BOXR), an approach for improving T cell functionality to enable solid tumor cancer applications. ACTR707 used in combination with rituximab, an anti-CD20 antibody, is Unum’s most advanced product candidate, currently in Phase I clinical testing in adult patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The Company has an additional product candidate in Phase I clinical testing: ACTR087 used in combination with the novel antibody SEA-BCMA in adult patients with relapsed or refractory multiple myeloma. Finally, the Company has an active investigational new drug application (IND) for ACTR707 used in combination with trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) antibody, to treat patients with HER2+ advanced cancer. This Phase I trial is expected to be initiated by the end of 2018.

The Company is headquartered in Cambridge, MA.

Forward looking Statements

This press release contains forward-looking statements. Statements in this press release about our future expectations, plans and prospects, our long-term growth, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates, including the ACTR and BOXR product candidates, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to the accuracy of our estimates regarding expenses, future revenues, capital requirements, and the need for additional financing, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Investor Contact:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com 

Media Contact:
Paul Kidwell, 617-680-1088
paul.kidwell@unumrx.com

UnumLogo.jpg

Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.